FDA Rejects Biodel’s Diabetes Drug: Biotech's Latest Mishaps
A bit of a mess but it's not over...
http://seekingalpha.com/article/235229-fda-rejects-biodels-diabetes-drug-biotech-s-latest-mishaps
See also...
Arena Pharmaceuticals, Inc. announced that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010. APD597 is a GPR119 agonist intended for the treatment of type 2
http://www.fiercebiotech.com/press-...pr119-portfolio-type-2-diabetes#ixzz14g4Uk9tx
But better news...
FDA Approves Kombiglyze
http://www.astrazeneca.com/media/la...ombiglyze-xr-tablets-approved?itemId=11756200
According to AstraZeneca and Bristol-Myers Squibb "Kombiglyze XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across glycosylated haemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG)."
A bit of a mess but it's not over...
http://seekingalpha.com/article/235229-fda-rejects-biodels-diabetes-drug-biotech-s-latest-mishaps
See also...
Arena Pharmaceuticals, Inc. announced that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010. APD597 is a GPR119 agonist intended for the treatment of type 2
http://www.fiercebiotech.com/press-...pr119-portfolio-type-2-diabetes#ixzz14g4Uk9tx
But better news...
FDA Approves Kombiglyze
http://www.astrazeneca.com/media/la...ombiglyze-xr-tablets-approved?itemId=11756200
According to AstraZeneca and Bristol-Myers Squibb "Kombiglyze XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across glycosylated haemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG)."